Insiders Sold Voyager Therapeutics Prematurely At US$7.47 With Stock Trading Higher

Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) stock price has dropped 24% in the previous week, but insiders who sold US$411k in stock over the past year have had less luck. The average selling price of US$7.47 is still lower than the current share price, or in other words, insiders would have been better off holding on to their shares.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Voyager Therapeutics

The Last 12 Months Of Insider Transactions At Voyager Therapeutics

The President, Alfred Sandrock, made the biggest insider sale in the last 12 months. That single transaction was for US$119k worth of shares at a price of US$9.86 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$4.21. So it may not tell us anything about how insiders feel about the current share price.

In the last year Voyager Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

Insiders At Voyager Therapeutics Have Sold Stock Recently

The last three months saw significant insider selling at Voyager Therapeutics. In total, insiders sold US$59k worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

Insider Ownership Of Voyager Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Based on our data, Voyager Therapeutics insiders have about 1.0% of the stock, worth approximately US$2.8m. We consider this fairly low insider ownership.

What Might The Insider Transactions At Voyager Therapeutics Tell Us?

Insiders sold Voyager Therapeutics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Voyager Therapeutics. Be aware that Voyager Therapeutics is showing 3 warning signs in our investment analysis, and 1 of those can't be ignored...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.